These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31765733)

  • 1. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
    Doloff JC; Waxman DJ
    BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
    Vergato C; Doshi KA; Roblyer D; Waxman DJ
    Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Doloff JC; Waxman DJ
    Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
    Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
    Front Immunol; 2020; 11():1376. PubMed ID: 32695118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
    Yin P; Li H; Ke C; Cao G; Xin X; Hu J; Cai X; Li L; Liu X; Du B
    Int J Nanomedicine; 2020; 15():1499-1515. PubMed ID: 32189965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
    Wu J; Waxman DJ
    Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
    Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
    Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
    Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
    Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.